Literature DB >> 27186971

Huaiqihuang may protect from proteinuria by resisting MPC5 podocyte damage via targeting p-ERK/CHOP pathway.

Tingxia Li1, Jianhua Mao, Lei Huang, Haidong Fu, Shuohui Chen, Aimin Liu, Yuqin Liang.   

Abstract

The purpose of this study was to investigate the potential effects of Huaiqihuang (HQH) granule, a Chinese herbal medicine, in treating proteinuria and to reveal its possible mechanism. MPC5 podocytes were cultured in vitro at 37°C and induced with tunicamycin (TM). The TM-induced cells were treated with HQH at different concentrations. The cell proliferation was detected using the MTT assay. The optimal effective dose of HQH for MPC5 cells was determined by the MTT assay and LDH assay respectively. The influences of HQH on the proteinuria-related protein expression and the signaling pathway associated protein expression were also detected using quantitative reverse transcription PCR and Western blotting analysis. The results showed that the MPC5 cell model was successfully constructed in vitro. The HQH application could improve the harmful effects induced by TM on the MPC5 cells, including promoted cell proliferation and suppressed cell apoptosis. Furthermore, the protein expression, including podocin, nephrin, and synaptopodin was down-regulated by the TM treatment in the MPC5 cells. On contrary, the expression of these proteins was up-regulated after the HQH application. Also, the effect of TM on integrin α3 and integrin β1 expressions was also reversed by the HQH treatment. Moreover, the HQH application decreased the expression of p-ERK and DNA-damage-inducible transcript 3 (DDIT3 or CHOP) in the MPC5 cells, which was opposite to the effect observed in the cells treated with TM. Taken together, our study suggest that HQH application may protect podocytes from TM damage by suppressing the p-ERK/CHOP signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27186971      PMCID: PMC4978111          DOI: 10.17305/bjbms.2016.887

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  26 in total

Review 1.  Mitogen-activated protein kinases.

Authors:  Saman Arbabi; Ronald V Maier
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

2.  Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia.

Authors:  Vesna D Garovic; Steven J Wagner; Lydia M Petrovic; Catherine E Gray; Pauline Hall; Hikaru Sugimoto; Raghu Kalluri; Joseph P Grande
Journal:  Nephrol Dial Transplant       Date:  2007-01-25       Impact factor: 5.992

Review 3.  The role of podocytes in proteinuria.

Authors:  Katsuhiko Asanuma; Etsuko Yanagida-Asanuma; Miyuki Takagi; Fumiko Kodama; Yasuhiko Tomino
Journal:  Nephrology (Carlton)       Date:  2007-12       Impact factor: 2.506

4.  Validation of an LDH assay for assessing nanoparticle toxicity.

Authors:  Xianglu Han; Robert Gelein; Nancy Corson; Pamela Wade-Mercer; Jingkun Jiang; Pratim Biswas; Jacob N Finkelstein; Alison Elder; Günter Oberdörster
Journal:  Toxicology       Date:  2011-06-23       Impact factor: 4.221

5.  [Effects of Chinese herbal medicine Huaiqihuang Granule on nephrin and podocin expressions in renal tissues of rats with adriamycin-induced nephrosis].

Authors:  Wen Sun; Zhi Zhu; Jian Yu; Yong-hong Wang; Man Xiong; Xia Gao; Zhong-hua Zhao; Xue-guang Liu
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2011-05

6.  Induction of diabetes in aged C57B6 mice results in severe nephropathy: an association with oxidative stress, endoplasmic reticulum stress, and inflammation.

Authors:  Jin Wu; Ruihua Zhang; Massimo Torreggiani; Adrian Ting; Huabao Xiong; Gary E Striker; Helen Vlassara; Feng Zheng
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

7.  Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.

Authors:  Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Marcia Landa; Giuseppe Maschio; Paul E de Jong; Dick de Zeeuw; Shahnaz Shahinfar; Robert Toto; Andrew S Levey
Journal:  Ann Intern Med       Date:  2003-08-19       Impact factor: 25.391

8.  Glucocorticoid receptors, in vitro steroid sensitivity, and cytokine secretion in idiopathic nephrotic syndrome.

Authors:  Ana Paula de Carvalho Panzeri Carlotti; Paulo Benedito Franco; Lucila Leico Elias; Inalda Facincani; Elaine Lourenço Cardeal Costa; Norma Foss; Ayrton Custódio Moreira; Margaret de Castro
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

Review 9.  Cell biology of the glomerular podocyte.

Authors:  Hermann Pavenstädt; Wilhelm Kriz; Matthias Kretzler
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

10.  Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.

Authors:  Shinobu Miyazaki-Anzai; Masashi Masuda; Kimberly M Demos-Davies; Audrey L Keenan; Sommer J Saunders; Rumiko Masuda; Kristen Jablonski; Maria A Cavasin; Jessica Kendrick; Michel Chonchol; Timothy A McKinsey; Moshe Levi; Makoto Miyazaki
Journal:  J Am Heart Assoc       Date:  2014-06-24       Impact factor: 5.501

View more
  10 in total

1.  Effectiveness of Huai Qi Huang Granules on Juvenile Collagen-induced Arthritis and Its Influence on Pyroptosis Pathway in Synovial Tissue.

Authors:  Ting He; Xie Xu; Xin-Yan Zhang; Pan Shen; Jia-Yun Ling; Yan-Xin-Li Han; Yu Wen; Xiu-Fen Hu; Hui-Ling Lu
Journal:  Curr Med Sci       Date:  2019-10-14

Review 2.  A Review of Traditional Chinese Medicine in Treating Renal Interstitial Fibrosis via Endoplasmic Reticulum Stress-Mediated Apoptosis.

Authors:  Yu Liu; Dan-Qian Chen; Jing-Xue Han; Ting-Ting Zhao; Shu-Ju Li
Journal:  Biomed Res Int       Date:  2021-05-15       Impact factor: 3.246

3.  Effect of Huaiqihuang Granules Combined with Comprehensive Nursing on Children with Primary Nephrotic Syndrome.

Authors:  Guiyun Yang; Huanqin Yang; Shifang Cui; Jinling Shan
Journal:  J Healthc Eng       Date:  2022-01-15       Impact factor: 2.682

4.  Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials.

Authors:  Xue Xue; Xue-Han Liu; Chun-Li Lu; Xin-Yan Jin; Qiang Liu; Xiao-Qin Wang; Jian-Ping Liu
Journal:  BMC Complement Med Ther       Date:  2021-11-08

Review 5.  Recent Advances in Traditional Chinese Medicine for Treatment of Podocyte Injury.

Authors:  Tianwen Yao; Wenxiang Su; Shisheng Han; Yan Lu; Yanqiu Xu; Min Chen; Yi Wang
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

Review 6.  Traditional Chinese Medicine in Treating Primary Podocytosis: From Fundamental Science to Clinical Research.

Authors:  Lirong Lin; En Tian; Jiangwen Ren; Zhifeng Wu; Junhui Deng; Jurong Yang
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

Review 7.  Efficacy and safety of Huaiqihuang granule as adjuvant treatment for primary nephrotic syndrome in children: a meta-analysis and systematic review.

Authors:  Jiao Lin; Li-Min Huang; Jing-Jing Wang; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2021-06-01       Impact factor: 2.764

8.  Pretreatment of Huaiqihuang extractum protects against cisplatin-induced nephrotoxicity.

Authors:  Yujiao Guo; Meng Wang; Jingyi Mou; Zhi Zhao; Juan Yang; Fengming Zhu; Guangchang Pei; Han Zhu; Yuxi Wang; Gang Xu; Rui Zeng; Ying Yao
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

Review 9.  The Effect of Chinese Traditional Medicine Huaiqihuang (HQH) on the Protection of Nephropathy.

Authors:  Xueyan Zhang; Yiyu Cheng; Qian Zhou; Haojie Huang; Yinmiao Dong; Yang Yang; Mingyi Zhao; Qingnan He
Journal:  Oxid Med Cell Longev       Date:  2020-06-16       Impact factor: 6.543

10.  Evaluation of Preclinical and Clinical Studies Published in Medical Journals of Bosnia and Herzegovina: Methodology Issues.

Authors:  Slobodan M Jankovic; Izet Masic
Journal:  Acta Inform Med       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.